Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03770260 · ClinicalTrials.gov registry record · Phase 1
Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to Treatment
A Phase 1 study of Refractory Multiple Myeloma and Recurrent Multiple Myeloma, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
- 9
- Study locations
NCT03770260: Completed Phase 1 study of Refractory Multiple Myeloma and Recurrent Multiple Myeloma, sponsored by National Cancer Institute (NCI).
NCT03770260 is a Phase 1 study of Refractory Multiple Myeloma and Recurrent Multiple Myeloma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 8 participants, below the 48-participant average among 67 other Refractory Multiple Myeloma trials with a reported enrollment target (83% lower). The trial reports 9 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03770260, a Phase 1 study of Refractory Multiple Myeloma and Recurrent Multiple Myeloma, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
- 9
- Study locations
Study Summary
This phase Ib trial studies side effects and best dose of pevonedistat when given together with ixazomib in treating patients with multiple myeloma that has come back or does not respond to treatment. Pevonedistat and ixazomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Primary Outcome
Number of participants experiencing a dose limiting toxicity to determine the maximum tolerated dose (MTD)
Conditions Studied
Interventions
- DRUG Ixazomib Citrate
- DRUG Pevonedistat
Study Locations (9)
Florida
- Moffitt Cancer Center-International Plaza - Tampa
- Moffitt Cancer Center - McKinley Campus - Tampa
- Moffitt Cancer Center - Tampa
Connecticut
- Smilow Cancer Center/Yale-New Haven Hospital - New Haven
- Yale University - New Haven
Georgia
- Emory University Hospital/Winship Cancer Institute - Atlanta
Kentucky
- University of Kentucky/Markey Cancer Center - Lexington
North Carolina
- Duke University Medical Center - Durham
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2020-02-10 |
| Est. Completion | 2023-07-06 |
| Phase | Phase 1 |
What the finished NCT03770260 record still lists
NCT03770260 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 48-participant average among 67 other Refractory Multiple Myeloma trials with a reported enrollment target (83% lower).
The record links to 2 conditions, with Refractory Multiple Myeloma appearing as the primary indexed condition, and to 2 interventions - of which Ixazomib Citrate is the first listed.
NCT03770260 lists 9 locations in 6 states (Florida, Connecticut, Georgia).
Frequently Asked Questions
What is clinical trial NCT03770260 about?
NCT03770260 is a clinical study titled "Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to Treatment". This phase Ib trial studies side effects and best dose of pevonedistat when given together with ixazomib in treating patients with multiple myeloma that has come back or does not respond to treatment. Pevonedistat and ixazomib may stop the growth of tumor cells by blocking some of the enzymes needed...
What is the current status of trial NCT03770260?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2020-02-10. Estimated completion is 2023-07-06.
What conditions does trial NCT03770260 study?
This clinical trial studies the following conditions: Refractory Multiple Myeloma, Recurrent Multiple Myeloma.
What interventions are being tested in trial NCT03770260?
The interventions under investigation include: Ixazomib Citrate (DRUG), Pevonedistat (DRUG).
Who is sponsoring clinical trial NCT03770260?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03770260 being conducted?
This trial has 9 study locations across Connecticut, Florida, Georgia, Kentucky, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Refractory Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03770260's enrollment target sits among peer trials
8 63rd of 67 higher than 5 of 67 other Refractory Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Refractory Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
RECRUITING · Phase 1
-
Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI